DBV Technologies SA - American (DBVT) AI Stock Analysis

• Market Cap: $250.85M
• Dividend Yield: N/A
• Average Volume (3M): 36.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.12
• Revenue Growth: N/A
• EPS Growth: -22.49%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 27,395,031
• 10 Day Avg. Volume: 22,116
• 30 Day Avg. Volume: 36,666
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: 76.60
• Enterprise Value/Gross Profit: -16.14
• Enterprise Value/Ebitda: -1.05
• 1Y Price Target: $18.67
• Price Target Upside: 102.49% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 48 Neutral
• Price Target: $9.00 ▼(-2.39% Downside)

DBV Technologies SA's overall score is primarily impacted by financial instability and weak technical indicators. The positive corporate event provides some optimism, but significant financial and operational challenges remain. The stock's valuation is unattractive due to unprofitability and lack of dividends.

Positive Factors

Financial Position

DBV secured a structured financing deal in March of up to $306.9M that is expected to support the company through commercialization in the US.

Market Potential

Viaskin Peanut has the potential to dramatically expand the market of children who undergo treatment for peanut allergies.

Regulatory Approval

FDA has formalized the Accelerated Approval pathway for the Viaskin Peanut patch, which could streamline the regulatory process.

Negative Factors

Approval Timeline

Success in the upcoming Phase 3 VITESSE trial will satisfy requirements for the BLA submission, currently planned for H1 2026.

Clinical Risk

The VITESSE trial in peanut-allergic children represents the last major clinical risk for the Viaskin Peanut program and is fully enrolled with a design informed by prior studies.

Competition

Omalizumab biosimilars are expected to become widely available, which may reduce constraints on coverage/reimbursement of a branded agent.

DBV Technologies SA - American Business Overview & Revenue Model

Company Description

DBV Technologies SA is a biopharmaceutical company focused on developing and commercializing innovative therapies for food allergies and immunological diseases. The company is primarily engaged in the research and development of its proprietary Viaskin technology, which aims to provide a safe and effective method for desensitizing patients to allergens through epicutaneous immunotherapy. DBV Technologies operates in the biotechnology sector, with a core emphasis on addressing unmet medical needs in allergy treatment.

How the Company Makes Money

DBV Technologies generates revenue primarily through the development and commercialization of its therapeutic products, particularly those that leverage its Viaskin technology for treating food allergies. The company may receive funding through partnerships with other pharmaceutical firms for co-development agreements, licensing deals, or joint ventures that provide upfront payments, milestone payments, and royalties on sales. Additionally, DBV Technologies may obtain revenue through government grants and research funding aimed at supporting the development of its innovative therapies. The company's earnings are significantly influenced by the successful progression of its clinical trials and the eventual commercialization of its products.

DBV Technologies SA - American Financial Statement Overview

Summary

DBV Technologies SA faces financial instability with declining revenues and persistent losses. The low leverage is positive, but negative returns and cash flow issues present significant challenges. The company needs to address revenue contraction and improve operational efficiency.

Income Statement

DBV Technologies SA has experienced a significant decline in revenue from $15.73 million in the previous year to $2.57 million in the TTM (Trailing-Twelve-Months), indicating a revenue contraction. The company also posted negative EBIT and net income margins, reflecting ongoing operational challenges and high expenses relative to revenue. Despite gross profit being positive, the net profit margin remains negative.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio, indicating limited leverage which is a positive aspect. However, the return on equity is negative due to the net losses, and the equity ratio has declined, indicating reduced financial stability. This suggests potential challenges in maintaining equity levels without external financing.

Cash Flow

DBV Technologies SA reported a negative free cash flow, with a deterioration in operating cash flow compared to the previous year. The free cash flow to net income ratio is negative, indicating cash flow issues. Despite a slight improvement in financing cash flow, the overall cash flow situation points to liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.58M	2.57M	15.73M	4.80M	5.71M	11.28M
Gross Profit	-7.51M	-4.26M	15.73M	-15.50M	-3.56M	11.28M
EBITDA	-115.51M	-111.18M	-85.98M	-76.68M	-91.16M	-124.83M
Net Income	-113.65M	-113.92M	-72.73M	-96.30M	-97.81M	-159.56M
Balance Sheet
Total Assets	143.43M	65.66M	182.99M	246.50M	146.72M	333.87M
Cash, Cash Equivalents and Short-Term Investments	103.21M	32.46M	141.37M	209.20M	77.30M	196.35M
Total Debt	14.59M	7.80M	6.55M	4.15M	10.66M	15.47M
Total Liabilities	57.20M	38.27M	42.80M	52.00M	47.45M	81.87M
Stockholders Equity	86.22M	27.39M	140.19M	194.50M	99.27M	205.49M
Cash Flow
Free Cash Flow	-88.56M	-106.81M	-80.33M	-56.45M	-109.16M	-206.48M
Operating Cash Flow	-88.28M	-104.47M	-79.65M	-55.70M	-108.24M	-203.10M
Investing Cash Flow	267.69K	-757.00K	-808.00K	-100.00K	-433.00K	-3.51M
Financing Cash Flow	118.61M	587.00K	6.77M	194.10M	274.00K	149.55M

DBV Technologies SA - American Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DBVT, the sentiment is Neutral. The current price of 9.22 is below the 20-day moving average (MA) of 9.67, below the 50-day MA of 9.76, and above the 200-day MA of 6.84, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 43.37 is Neutral, neither overbought nor oversold. The STOCH value of 18.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DBVT.

DBV Technologies SA - American Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	69 Neutral	$126.77M	21.49	15.99%	―	62.79%	―
CDTX	58 Neutral	$1.65B	―	-37.05%	―	-100.00%	55.31%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
DBVT	48 Neutral	$250.85M	―	-148.73%	―	―	-22.49%
ENGN	42 Neutral	$255.53M	―	-33.97%	―	―	―
CRVS	41 Neutral	$426.97M	―	-68.67%	―	―	-50.83%
CRGX	40 Underperform	$216.19M	―	-65.83%	―	―	-32.05%

DBV Technologies SA - American Corporate Events

DBV Technologies Launches $150M ATM Equity Offering

On September 5, 2025, DBV Technologies announced the establishment of an at-the-market (ATM) equity offering program on Nasdaq, allowing the company to sell up to $150 million in American Depositary Shares (ADS) through Citizens JMP Securities. The proceeds from this program are intended to support the Biologics License Application for the VIASKIN Peanut patch and other corporate purposes, with the sales being conducted at market prices and subject to regulatory limits.

DBV Technologies Launches COMFORT Toddlers Safety Study

On June 25, 2025, DBV Technologies announced the screening of the first subject in their COMFORT Toddlers supplemental safety study, which targets peanut-allergic toddlers aged 1 to 3 years. The study, involving approximately 480 subjects across multiple countries, aims to supplement safety and efficacy data for the Viaskin Peanut patch. This development marks a significant step towards potentially advancing the Viaskin Peanut patch to market, with data supporting a Biologics License Application submission anticipated in the second half of 2026 under the FDA’s Accelerated Approval Pathway. The initiation of this study underscores DBV Technologies’ commitment to addressing the unmet needs of food allergic patients.

DBV Technologies SA Approves Key Governance Amendments

On June 11, 2025, DBV Technologies SA held its Annual General Meeting where shareholders approved several resolutions, including the 2024 ex-post compensation for CEO Daniel Tassé and exceptional bonuses for other executives. Additionally, the meeting resulted in amendments to the company’s bylaws, allowing the Board of Directors to make decisions through written consultation and setting an age limit for the Chairman at 80 years. These changes reflect the company’s ongoing efforts to refine its governance structure and executive compensation policies, potentially impacting its operational efficiency and stakeholder relations.